TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17666281
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with plasma
Study: 16241020
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with morphine (BM)
Study: 10835489
Drug: Beta-carotene 30
Normalized name: beta-carotene 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene 30 mg/day
Study: 7649718
Drug: Methylphenidate (30
Normalized name: methylphenidate (30/70 release) 10 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (30 mg daily)
Study: 7649718
Drug: Desipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (150 mg daily)
Study: 2573312
Drug: Beta 2
Normalized name: Beta 2 globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2 adrenergic agonists (fenoterol, salbutamol, terbutaline)
Study: 23363007
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment program for female sexual dysfunction
Study: 23363007
Drug: Control participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control participants who elected to enter treatment
Study: 16740317
Drug: Sudarshana Kriya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sudarshana Kriya Yoga (SKY) therapy
Study: 16740317
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SKY therapy)
Study: 11041775
Drug: Pilocarpine hydrochloride
Normalized name: Pilocarpine Hydrochloride
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine hydrochloride (Salagen) 15 mg per day with a 5 mg optional increase at 5 weeks up to a daily dose of 25 mg beyond 9 weeks
Study: 6369290
Drug: Oral disopyramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disopyramide (300 mg loading dose, then 100 mg qds)
Study: 31202957
Drug: Ensifentrine 0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 0.4, 1.5, 6 and 24 mg
Study: 31202957
Drug: Salbutamol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 2.5 and 7.5 mg
Study: 26590876
Drug: Brief Integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Integrated Motivational Intervention (BIMI) with Treatment As Usual (TAU)
Study: 20166624
Drug: 0.5% morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% morphine drops
Study: 15570319
Drug: Phosphorus supplement
Normalized name: Phosphorus supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphorus supplement (taken three times a day for 2 weeks)
Study: 15570319
Drug: No phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No phosphorus supplement (4th week)
Study: 7784717
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of SRT
Study: 7784717
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of SRT
Study: 7784717
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of SRT
Study: 2150795
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cyproterone acetate (CPA) + 0.035 mg ethinyl estradiol (EE2) (Diane ‐35)
Study: 2150795
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cyproterone acetate (CPA) + 0.050 mg ethinyl estradiol (EE2) (Diane ‐50)
Study: 31865391
Drug: Plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen activator inhibitor-1 (PAI-1)
Study: 31905615
Drug: Quercetin-rich onion
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin-rich onion powder (9 g per day for 12 weeks)
Study: 22000449
Drug: Buccal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal plus palatal infiltrations
Study: 16320174
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (12 g CHO kgbm (‐1) . day (‐1))
Study: 12007668
Drug: Rapid titration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid titration regimen (150 mg/day reached at day five)
Study: 12007668
Drug: Slow titration
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow titration regimen (150 mg/day reached at day 15)
Study: 10477776
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (mean daily dose, 0.10 +/- 0.02 mg/kg)
Study: 10103699
Drug: Heparin 10
Normalized name: heparin 10 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 10 units/mL flushing solution
Study: 10103699
Drug: Saline flushing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flushing solution
Study: 347465
Drug: Maprotiline (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (oral dose of 75 or 150 mg per day)
Study: 25773819
Drug: 3D‐CRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐CRT plus tamoxifen (60 mg/m2/d)
Study: 25773819
Drug: 3D‐CRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D‐CRT plus temozolomide (75 mg/m2/d)
Study: 23642375
Drug: Oral omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega-3 (180 mg EPA and 120 mg DHA, 2 capsules daily for 30 days)
Study: 23642375
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 medium-chain triglyceride oil capsules daily for 1 month)
Study: 23642375
Drug: Oral omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega-3
Study: 19253803
Drug: Rehabilitation Swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation Swallowing Therapy (RST)
Study: 19253803
Drug: Neuromuscular Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular Electrical Stimulation Therapy (NMES)
Study: 9804602
Drug: All beverages
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beverages (WP, hypo-, iso-, and hypertonic solutions)
Study: 31605405
Drug: 6-mm-short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm-short implants
Study: 31605405
Drug: 11-mm-long implants
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-mm-long implants
Study: 29097444
Drug: Monthly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly subcutaneous injections of 3.6 mg goserelin and continuous 60 mg raloxifene daily orally for 2 years
Study: 20185598
Drug: Model predictive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model predictive control for dosing erythropoietin
Study: 18448978
Drug: Various vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various vaccine candidates (live attenuated, conjugate, broad spectrum, proteosome-based)
Study: 16145407
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release oxybutynin (5 to 30 mg daily, individualized dosing)
Study: 7930477
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (1 mg.kg‐1.min‐1) for 45 min
Study: 7930477
Drug: Euglycemic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycemic insulin clamp (1 mU.kg‐1.min‐1) for 2 hours
Study: 7930477
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin levels
Study: 3063718
Drug: Methylphenidate 0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.60 mg/kg
Study: 26222750
Drug: Metronidazole Vaginal
Normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Vaginal Gel 1.3%
Study: 26222750
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel
Study: 24397194
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon and ribavirin therapy for 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4)
Study: 19115219
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF, 300 mg)
Study: 19115219
Drug: Lamivudine (LMV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (LMV, 300 mg)
Study: 19115219
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (TDF/LMV)
Study: 11763011
Drug: Cyproheptadine 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine 16 mg/day
Study: 29082462
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with 940 nm diode laser, 7 sessions over 2 weeks
Study: 22067809
Drug: SILCS diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS diaphragm (single-sided gel delivery)
Study: 22067809
Drug: SILCS diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS diaphragm (double-sided gel delivery)
Study: 22067809
Drug: Gel applicator
Normalized name: PROGESTERONE 4% VAG GEL APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel applicator
Study: 22067809
Drug: SILCS diaphragm
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS diaphragm (single-sided and double-sided gel delivery)
Study: 20673054
Drug: 0.01% benzalkonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% benzalkonium chloride (BAC) solution, applied three times daily for 12 weeks
Study: 20673054
Drug: Placebo solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution, applied three times daily for 12 weeks
Study: 19128624
Drug: IT dexamethasone
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT dexamethasone injection
Study: 16394299
Drug: Pentavalent human-bovine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine
Study: 10390266
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy (6 doses at 12-hour intervals starting at 24 to 48 hours of life)
Study: 8695241
Drug: G-CSF +
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF + TS
Study: 1738412
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at 0.01 micrograms/min/kg
Study: 1738412
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at 0.05 micrograms/min/kg
Study: 1738412
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at 0.1 micrograms/min/kg
Study: 1738412
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving vehicle infusion without PGE1
Study: 6828682
Drug: Glucagon (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (0.05 mg/kg)
Study: 6828682
Drug: Placebo (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.05 mg/kg)
Study: 31607313
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose DAC 10 mg/(m2·d)×7 d
Study: 31607313
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose DAC 20 mg/(m2·d) ×5 d
Study: 31607313
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose DAC+CAG (DAC 10 mg/(m2·d) d 1‐5, cytarabine 10 mg/(m2·d) q12h d 1‐7, aclaromycin 10 mg/d d 1‐4, G‐CSF 200 μg/(m2·d), d 1‐7)
Study: 23495677
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day phosphatidylserine (PS) for 2 months
Study: 22081981
Drug: Iron-rich bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rich bread (2.2 mg iron per 50 g slice) consumed at an average of 2.3 slices per day for 6 weeks
Study: 20110052
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11 of two 21-day cycles plus ketoconazole 400 mg on days 6, 7, 8, and 9 of cycle 1
Study: 20110052
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11 of two 21-day cycles without ketoconazole
Study: 17488902
Drug: Amodiaquine 15
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine 15 mg/kg
Study: 9626150
Drug: 1 mU/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mU/min insulin
Study: 9626150
Drug: 5 mU/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mU/min insulin
Study: 2508260
Drug: dDAVP followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP followed by standard heparin
Study: 2508260
Drug: standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard heparin
Study: 808359
Drug: Chewable isosorbide
Normalized name: isosorbide dinitrate Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable isosorbide dinitrate (CHIS), 10 mg
Study: 808359
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG), 0.6 mg
Study: 808359
Drug: Placebo (P),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P), two chewable tablets
Study: 25438099
Drug: Conical implants
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical implants with wide pitch (group 1)
Study: 10889124
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of orbofiban twice daily (50/50 group)
Study: 10889124
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of orbofiban twice daily for 30 days followed by 30 mg of orbofiban twice daily (50/30 group)
Study: 1568517
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (1,200,000 IU given intramuscularly)
Study: 1568517
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (250 mg given orally twice daily)
Study: 1568517
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (250 mg given orally twice daily)
Study: 1568517
Drug: Roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (150 mg given orally once daily)
Study: 18003795
Drug: CCK-8 infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-8 infusion (2 ng.kg(‐1).min(‐1))
Study: 16556903
Drug: Local blockade
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local blockade of nitric oxide and prostaglandins using nitro‐L‐arginine methyl ester and indomethacin during one‐legged dynamic knee‐extension exercise
Study: 10932513
Drug: Cefazolin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (50 mg/ml) and fortified gentamicin (14 mg/ml)
Study: 9298049
Drug: Topical aminocaproic
Normalized name: aminocaproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aminocaproic acid
Study: 8393888
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg) with 1 microgram/kg ovine CRH
Study: 8393888
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg) with 0.25 microgram ACTH-(1-24)
Study: 7923235
Drug: Vigabatrin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin treatment
Study: 19086331
Drug: Enteral lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral lansoprazole (LODT) 30 mg mixed in 10 mL of water via a nasal gastric tube
Study: 19086331
Drug: Intravenous lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lansoprazole (IV-L) 30 mg over 30 min
Study: 17073356
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading implants (control)
Study: 10714402
Drug: Low-dose clonazepam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose clonazepam (CZP) 0.02 mg/kg BW
Study: 10146966
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine (mesalamine) at 1g, 2g, or 4g daily
Study: 27428073
Drug: Autologous tumour
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumour lysate dendritic cell vaccine (ADC) + best supportive care (BSC)
Study: 25498484
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) treatment initiated within 3 hours of injury
Study: 25498484
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) treatment initiated beyond 3 hours of injury
Study: 23424892
Drug: Corn tortilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn tortilla fortified with 20 mg/kg of zinc oxide
Study: 23424892
Drug: Corn tortilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn tortilla fortified with 20 mg/kg of zinc sulfate
Study: 23424892
Drug: Corn tortilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn tortilla with 30 mg/kg of iron added
Study: 23424892
Drug: Corn tortilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn tortilla with 60 mg/kg of iron added
Study: 18715434
Drug: Cocoa butter
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa butter lotion
Study: 20428365
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment for all household members
Study: 31422414
Drug: 5-gene combination
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-gene combination
Study: 20943454
Drug: CON‐IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON‐IFN plus lamivudine combination therapy
Study: 20943454
Drug: PEG‐IFN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN plus lamivudine combination therapy
Study: 16114156
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily (n=125)
Study: 16114156
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg daily (n=125)
Study: 2325572
Drug: Low-dose calcitriol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcitriol (0.25 micrograms twice daily)
Study: 2325572
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,000 mg/d)
Study: 6997734
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose of aqueous penicillin G given at birth
Study: 24866894
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.6µg/kg/hour)
Study: 25636764
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with irradiation to the internal mammary lymph node (IMN) (Arm 2)
Study: 25636764
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy without irradiation to the internal mammary lymph node (IMN) (Arm 1)
Study: 24781178
Drug: Tonsilgon N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsilgon N (herbal preparation)
Study: 24781178
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no herbal preparation)
Study: 15563538
Drug: Celecoxib (COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (COX-2 inhibitor)
Study: 9833917
Drug: Protein solution
Normalized name: Plasma protein solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein solution
Study: 8125392
Drug: Parenteral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral feeding for 15 days
Study: 2573444
Drug: MK‐912 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐912 2.0 mg
Study: 2573444
Drug: MK‐912 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐912 1.0 mg
Study: 795007
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg i.v. per day
Study: 795007
Drug: Benzylpenicillin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzylpenicillin 10 million I.U. 4 times a day and streptomycin 500 mg twice a day
Study: 15274404
Drug: Cisplatin-gemcitabine (CG)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-gemcitabine (CG) - gemcitabine 1125 mg/m2 (days 1 and 8) plus cisplatin 80 mg/m2 (day 2) every 3 weeks for a maximum of 5 cycles
Study: 15274404
Drug: Epirubicin-gemcitabine (EG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-gemcitabine (EG) - gemcitabine 1125 mg/m2 (days 1 and 8) plus epirubicin 100 mg/m2 (day 1) every 3 weeks for a maximum of 5 cycles
Study: 11534915
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream 0.02%